News Roundup: HUYA Inc. (NYSE:HUYA), ImmunoGen, Inc. (NASDAQ:IMGN)



HUYA Inc. (NYSE:HUYA) represented a move of -0.21 percent or $-0.07 per share and closed its previous day trading session at $19. 2.19 Million Shares were traded in the last trading session with an Average Volume of 2.11 Million Shares. The stock currently has a Market Capitalization of 3.83 Billion.

HUYA Inc. provides online services. The Company offers interactive video broadcast service which includes e-sports, music, reality show and more. HUYA based in Guangzhou, China.

The stock traded between $15.25 and $50.82 over 1-Year time period showing its price to sales ratio of 8.28.

Right now, the stock has a 50-Day Simple Moving Average of $-17.27 and 200-Day Simple Moving Average of $-31.73. Its Price to Free Cash Flow is 0 and Price to Book of 5.12.

Analyst’s recommended the stock as 2.6 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, HUYA Inc. (NYSE:HUYA) reported its Actual EPS of $0.05/share. The analysts offering Earnings Estimates for the company were believing that HUYA Inc. could bring EPS of $0.06/share. The difference between Actual EPS and Estimated EPS was -0.01 Percent. Thus showing an Earnings Surprise of -16.7 Percent.

ImmunoGen, Inc. (NASDAQ:IMGN)

In the last trading session, ImmunoGen, Inc. (NASDAQ:IMGN) added its value by 0.81% closing at the price of $6.22. The stock currently has market capitalization of 971.07 Million, with average volume of 2.1 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently ImmunoGen, Inc. (NASDAQ:IMGN) is showing beta of 2.56. This particular value of beta suggests that ImmunoGen, Inc. (NASDAQ:IMGN) has historically moved 256% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for ImmunoGen, Inc. (NASDAQ:IMGN) is at $-1.32.

The stock currently has RSI of 42.73. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company’s product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.

ImmunoGen, Inc. (NASDAQ:IMGN) topped its 52-week high price of $13.41 on 03/26/18 and 52-Week Low Price of $ 5.24 on 11/06/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 10.33% and monthly volatility of 8.99% respectively.